Aligos Therapeutics, Inc.
As of Oct 22, 2026, Aligos Therapeutics is in Stage 1, the basing phase, now in week 2 (since Oct 13, 2026). It closed at $4.82, 63.7% below its 52-week high and below its 200-day average, which is falling.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ALGS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ALGS among Biotechnology368th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …368 | ALGS | Stage 1 · wk 2 | 22 | −13.3% |
Aligos Therapeutics: quick answers
What stage is Aligos Therapeutics in?
As of Oct 22, 2026, Aligos Therapeutics (ALGS) is in Stage 1, the basing phase. It entered Stage 1 on Oct 13, 2026 and is in week 2. What the four stages mean
Is Aligos Therapeutics in an uptrend?
Not yet. Aligos Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 24.4% below its 200-day average, which is falling.
How far is Aligos Therapeutics from its 52-week high?
Aligos Therapeutics closed at $4.82 on Oct 22, 2026, 63.7% below its 52-week high of $13.30. Its 52-week low is $4.08.
How has Aligos Therapeutics performed over the past year?
As of Oct 22, 2026, Aligos Therapeutics is down 54.1% over the past year and down 47.2% so far in 2026.
Which sector and industry is Aligos Therapeutics in?
Aligos Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.